LYCOS RETRIEVER 
Obstetrics: Rush University
built 650 days ago
Jacobus Pfisterer, M.D., Ph.D., current president of the Gynecologic Cancer Intergroup (GCIG), and professor of gynecology and obstetrics at the University of Heidelberg in Germany, was the principal investigator of the GEMZAR plus carboplatin study. The randomized Phase III study compared GEMZAR plus carboplatin against carboplatin (a platinum-based chemotherapy) alone in locally advanced or metastatic disease in patients previously treated with platinum-based therapy such as carboplatin or cisplatin. The primary endpoint of this 356-patient trial was progression-free survival, the measure of time after cancer is treated until the disease begins to worsen. Many ovarian cancer patients will receive additional treatments each time their disease recurs. Progression-free survival as an endpoint is a meaningful measurement because it is not influenced by subsequent treatments. Response rate, safety and survival were secondary endpoints.
Source:
The University of Kentucky's Department of Obstetrics and Gynecology was founded in 1962. Since its beginning, the department has continued to focus on providing outstanding patient care as well as providing an educational atmosphere for the training and education of medical students and residents in the field of obstetrics and gynecology.
Source:
Howard T. Strassner, Jr., MD, is chairperson of the Department of Obstetrics and Gynecology at Rush University Medical Center. Dr. Strassner is the John M. Simpson Professor of Obstetrics and Gynecology at Rush University. For profiles of physicians specializing in obstetrics and gynecology or related areas, see the link at left for “Find a Doctor.”
Source:
MORE ABOUT
Rush University